Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.

The nonapeptide hormones arginine vasopressin (CYFQNCPRG-NH2, AVP) and oxytocin (CYIQNCPLG-NH2, OT), control many essential functions in mammals. Their main activities include the urine concentration (via stimulation of AVP V2 receptors, V2R, in the kidneys), blood pressure regulation (via stimulation of vascular V1a AVP receptors, V1aR), ACTH control (via stimulation of V1b receptors, V1bR, in the pituitary) and labor and lactation control (via stimulation of OT receptors, OTR, in the uterus and nipples, respectively). All four receptor subtypes belong to the GTP-binding (G) protein-coupled receptor (GPCR) family. This work consists of docking of YM087, a potent non-peptide V1aR and V2R – but not OTR – antagonist, into the receptor models based on relatively new theoretical templates of rhodopsin (RD) and opiate receptors, proposed by Mosberg et al. (Univ. of Michigan, Ann Arbor, USA). It is simultaneously demonstrated that this RD template satisfactorily compares with the first historical GPCR structure of bovine rhodopsin (Palczewski et al., 2000) and that homology-modeling of V2R, V1aR and OTR using opiate receptors as templates is rational, based on relatively high (20–60%) sequence homology among the set of 4 neurophyseal and 4 opiate receptors. YM087 was computer-docked to V1aR, V2R and OTR using the AutoDock (Olson et al., Scripps Research Institute, La Jolla, USA) and subsequently relaxed using restrained simulated annealing and molecular dynamics, as implemented in AMBER program (Kollman et al., University of California, San Francisco, USA). From about 80 diverse configurations, sampled for each of the three ligand/receptor systems, 3 best energy-relaxed complexes were selected for mutual comparisons. Similar docking modes were found for the YM087/V1aR and YM087/V2R complexes, diverse from those of the YM087/OTR complexes, in agreement with the molecular affinity data.

[1]  A. Scheer,et al.  Constitutively active mutants of the alpha 1B‐adrenergic receptor: role of highly conserved polar amino acids in receptor activation. , 1996, The EMBO journal.

[2]  C. Czaplewski,et al.  Molecular modelling of the vasopressin V2 receptor/antagonist interactions. , 1998, Acta biochimica Polonica.

[3]  J. Baldwin.  The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.

[4]  Y. Shimonishi.  Peptide Science — Present and Future , 2002, Springer Netherlands.

[5]  Yoshitaka Yamamura,et al.  Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist , 1992, British journal of pharmacology.

[6]  M C Peitsch,et al.  Automated modelling of the transmembrane region of G-protein coupled receptor by Swiss-model. , 1996, Receptors & channels.

[7]  J. Wess.  G‐protein‐coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G‐protein recognition , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  F. Fanelli,et al.  Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis. , 1999, Molecular pharmacology.

[9]  B. Kobilka,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[10]  H. Koshio,et al.  Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives. , 2000, Chemical & pharmaceutical bulletin.

[11]  K. Nakanishi,et al.  Movement of retinal along the visual transduction path. , 2000, Science.

[12]  J Hoflack,et al.  Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. , 1995, The EMBO journal.

[13]  M. Shoham,et al.  A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor. , 2000, The Journal of pharmacology and experimental therapeutics.

[14]  Gebhard F. X. Schertler,et al.  Arrangement of rhodopsin transmembrane α-helices , 1997, Nature.

[15]  C. Humblet,et al.  G-Protein coupled receptors: models, mutagenesis, and drug design. , 1998, Journal of medicinal chemistry.

[16]  M. Grossmann,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[17]  F. Corpet.  Multiple sequence alignment with hierarchical clustering. , 1988, Nucleic acids research.

[18]  A. Lomize,et al.  Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. , 1998, Biophysical journal.

[19]  C. Czaplewski,et al.  Molecular modeling of the oxytocin receptor/bioligand interactions. , 1999, Acta biochimica Polonica.

[20]  J. Shine,et al.  G protein-coupled receptors , 1992, Current Biology.

[21]  J Hoflack,et al.  The Binding Site of Neuropeptide Vasopressin V1a Receptor , 1995, The Journal of Biological Chemistry.

[22]  Y. Yamamura,et al.  OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. , 1991, Science.

[23]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[24]  P Herzyk,et al.  Automated method for modeling seven-helix transmembrane receptors from experimental data. , 1995, Biophysical journal.

[25]  C. Johnston,et al.  In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat. , 1999, European journal of pharmacology.

[26]  David S. Goodsell,et al.  Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 , 1996, J. Comput. Aided Mol. Des..

[27]  M. Manning,et al.  Discovery, development, and some uses of vasopressin and oxytocin antagonists. , 1989, The Journal of laboratory and clinical medicine.

[28]  E. Tribollet,et al.  Vasopressin and oxytocin receptors in the central nervous system. , 1996, Critical reviews in neurobiology.

[29]  N. Cotte,et al.  Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. , 2000, European journal of biochemistry.

[30]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[31]  C. S. Gal,et al.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. , 1996, The Journal of clinical investigation.

[32]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[33]  M. Takanashi,et al.  Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. , 1997, The Journal of pharmacology and experimental therapeutics.

[34]  Mark S. Gordon,et al.  General atomic and molecular electronic structure system , 1993, J. Comput. Chem..

[35]  J. Baldwin,et al.  An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. , 1997, Journal of molecular biology.

[36]  T. Takenaka,et al.  Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs. , 1997, European journal of pharmacology.